Ardelyx (ARDX) Announced New data for IBSRELA

Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best American Penny Stocks to Buy According to Analysts. On May 6, Ardelyx, Inc. (NASDAQ:ARDX) announced new data for IBSRELA at the Digestive Disease Week 2025 Conference.

IBSRELA is FDA-approved treatment for adults with irritable bowel syndrome with constipation. Management highlighted results from the IBS in America 2024 survey. The findings show that people with more severe IBS-C symptoms often face greater financial stress. This was measured using FACIT-COST and PROMIS-GI tools. Moreover, people with worse symptoms reported higher financial hardship.

The company also presented new data from a Phase 3 pediatric study, where IBSRELA was tested in patients aged 12 to under 18 with IBS-C. The results show that the medicine was well-tolerated, with the only side effect being diarrhea.

Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines.

While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.